Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →Filing growth compares 2021 (439 records) with 2024 (444) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 8,714 records in scope (CR5), not by the ranked leaders only.
This dataset tracks patent families addressing subcutaneous administration, hyaluronidase coformulation, and large volume injection, cross-referenced against the practical obstacles that make subcutaneous delivery hard: injection site reaction, bioavailability variability, dispersion in tissue, volume limits, pain perception, and device pairing. The scope spans 8,714 published records filed between 2015 and mid-2026.
The picture that emerges is a formulation-heavy field. Most activity clusters around medicinal preparation claims and peptide or protein chemistry, with a smaller but persistent layer of genetic engineering and heterocyclic compound filings. Concentration at the top is real but not extreme — the leader holds 843 records against a field of 8,714, leaving substantial room below the top ranks.
Pick a task. Every answer cites the patents behind it.
Two views of the same 8,714 records: how filing volume has moved year over year, and which IPC subclasses carry the claim weight.
Filings ran from 454 in 2017 to a peak of 535 in 2019, then held roughly flat through the recent complete years — 439 in 2021 versus 444 in 2024, a +1% span. The 2025 and 2026 figures (49 for the partial latest year) understate true filing activity because publication typically lags filing by around 18 months.
A61K (medicinal preparations) covers 79.2% of the 8,714 records, far ahead of A61P (therapeutic activity, 48.8%) and C07K (peptides and proteins, 33.7%). Genetic engineering (C12N, 22.8%) and nucleic acid chemistry (C07H, 8.8%) form a smaller secondary layer. Because records carry multiple IPC codes, these shares sum to well over 100% and should be read against the full record count, not against each other.
Shares are the percentage of the 8,714 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
This page is one run against one query. Ask Eureka your own question about subcutaneous delivery and hyaluronidase and every answer comes back with the patent numbers behind it.
Try EurekaProvided are combinations, compositions and kits containing a bisphosphonate composition and a soluble hyaluronidase composition formulated for subcutaneous administration. Such products can be used in methods of treating bisphosphonate-treatable diseases or conditions. Also provided are methods for subcutaneous administration of a bisphosphonate compound whereby the dosing regimen is substantially the same as for intravenous administration of the same dosage for treatment of the same bisphosphonate-treatable disease or condition.Filed by Halozyme, Inc., published 2009-10-22 — a foundational example of the hyaluronidase-coformulation approach that recurs across later filings in this dataset.
View full filing| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | WO2009006478A2 | 6-disubstituted bicyclic nucleic acid analogs | 1,261 |
| 2 | WO2008150729A2 | N-substituted-aminomethylene bridged bicyclic nucleic acid analogs | 1,255 |
| 3 | WO2008154401A2 | Carbocyclic bicyclic nucleic acid analogs | 1,249 |
| 4 | WO2008101157A1 | 5'-substituted-2'-f modified nucleosides and oligomeric compounds prepared therefrom | 976 |
| 5 | WO2011140249A2 | Antibodies that bind CSF1r | 811 |
| 6 | WO2013169264A1 | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1r) | 690 |
| 7 | WO2014036357A1 | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1r) | 687 |
| 8 | US8278425B2 | <i>N</i>-substituted-aminomethylene bridged bicyclic nucleic acid analogs | 640 |
| 9 | US8278283B2 | 6-disubstituted or unsaturated bicyclic nucleic acid analogs | 633 |
| 10 | US8278426B2 | Carbocyclic bicyclic nucleic acid analogs | 632 |
Citation counts favour older filings simply because they have had longer to accumulate citations inside this corpus — treat them as a signal of influence, not of current importance. Several of the highest-cited records relate to nucleic acid chemistry rather than subcutaneous delivery mechanics directly, reflecting how broadly the search terms pull in adjacent biologics chemistry.
Each row carries its publication number; clicking a row searches Eureka by that number.
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →Three findings that shape where a new filing is likely to clear and where it will collide with dense prior art.
Five assignees hold 2,567 of the 8,714 records in scope, and the leader alone accounts for 843. That leaves a long tail below tenth place (174 records) where filing density drops off quickly, suggesting formulation-specific niches are still open even as the broad hyaluronidase-coformulation approach is well covered near the top.
Complete-year filing counts moved from 439 in 2021 to 444 in 2024 — essentially flat. Figures for 2025 and 2026 are lower only because publication lags filing by roughly 18 months; they should not be read as a slowdown.
A61K medicinal preparation claims appear on the large majority of records, well ahead of genetic engineering (C12N, 22.8%) or analytical/testing classes (G01N, 3.7%). Device-pairing and dispersion-in-tissue language appears in the search terms but is thin in the IPC composition, pointing to a gap between the clinical problem and where claims are actually being written.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to subcutaneous delivery and hyaluronidase, with the prior art for and against each one.
| Assignee | Co-assignee | Shared families |
|---|---|---|
| Regeneron Pharmaceuticals | Sanofi Biotech | 360 |
| Genentech | Xenon Pharmaceuticals | 182 |
| Five Prime Therapeutics | Bristol-Myers Squibb | 145 |
| Genentech | F. Hoffmann-La Roche | 83 |
| Regulus Therapeutics | Board of Regents, The University of Texas System | 63 |
| Ionis Pharmaceuticals | SWAYZE ERIC E | 56 |
| Ionis Pharmaceuticals | BHANOT SANJAY | 38 |
| Ionis Pharmaceuticals | SETH PUNIT P | 37 |
Ten identified co-assignee pairs exist in this dataset, the strongest linking two large biologics filers at 360 shared records — evidence of sustained joint development programmes rather than one-off collaborations.
Recent-year momentum diverges sharply from historical volume: several of the largest historical filers show sharp year-over-year declines in the latest year, consistent with the publication lag rather than a genuine pullback.
The top-ranked assignee holds 843 of the 8,714 records in scope, well ahead of fifth place at 358 and tenth place at 174 — a steep drop-off that marks where the field opens up for newer entrants.
Several historically active assignees show latest-year filings at or near zero with YoY declines of -88% to -100%. This mirrors the roughly 18-month publication lag rather than an actual halt in R&D, so recent-year momentum figures should be read cautiously.
The strongest co-assignee relationship spans 360 shared records, with two further pairs at 182 and 145. These patterns typically reflect licensing or joint-development arrangements between a large-molecule originator and a formulation or hyaluronidase specialist.
| Assignee | Recent year | YoY |
|---|---|---|
| Regeneron Pharmaceuticals | 2 | -88% |
| Sanofi | 1 | 0% |
| Ionis Pharmaceuticals | 0 | -100% |
| Five Prime Therapeutics | 0 | -100% |
| Regulus Therapeutics | 0 | -100% |
| Sanofi Biotech | 0 | -100% |
| Genentech | 0 | -100% |
| Alkermes Pharma Ireland | 0 | -100% |
The landscape points to specific next steps depending on whether the goal is freedom-to-operate, licensing, or new filing strategy.
Given that 79.2% of records carry A61K medicinal preparation claims, any new subcutaneous formulation should be checked against this class specifically before drafting.
Explore claim scope in EurekaDevice-pairing and dispersion-in-tissue language appears thin in the IPC composition relative to the clinical need described in the search scope, which may indicate open claim space.
Map white space in EurekaLatest-year declines across several leading assignees are consistent with publication lag; revisit this trend once 2025-26 data matures.
Monitor assignee activity in EurekaIt is moderately concentrated but not closed. The top five assignees together hold 2,567 of the 8,714 records in scope, which is 29.5% of the field, and the single leader accounts for 843 records. Below the top ten, filing density drops off quickly — tenth place sits at 174 records — which leaves a long tail of entities with smaller, more specific filings. A new entrant is more likely to find open space in formulation niches than in the broad hyaluronidase-coformulation approach itself.
Filing volume has been essentially flat across the most recent complete years, moving from 439 records in 2021 to 444 in 2024, a rise of about 1%. The peak year so far was 2019 at 535 records. Figures for 2025 and 2026 look lower, but that reflects the roughly 18-month lag between filing and publication rather than an actual slowdown, so those years should not be used to call a trend.
Medicinal preparation claims under A61K appear on 79.2% of the 8,714 records, making it by far the most common classification, followed by therapeutic activity claims (A61P) at 48.8% and peptide and protein chemistry (C07K) at 33.7%. Genetic engineering (C12N) and nucleic acid chemistry (C07H) form smaller secondary layers. Because a single record can carry several IPC codes, these percentages add up to more than 100% and should each be read against the full 8,714-record base rather than against each other.
The clearest gaps sit in branches that the underlying clinical problem clearly touches but which are thin in the IPC composition — device-pairing for injection depth, dispersion-rate modelling in tissue, and pain-perception biomarkers tied to specific formulations. These areas show up in the search scope's core terms but are not well represented among the dominant A61K and C07K classifications. A first claim there would likely combine a formulation-specific trigger (viscosity, concentration, hyaluronidase ratio) with a measurable delivery outcome, rather than claiming the coformulation approach broadly.
The ranking covers 100 companies drawn from the full 8,714-record dataset, with the leader holding 843 records and a steep drop to 358 at fifth place and 174 at tenth. This is the complete ranked set the data returns, not a curated top 50 or top 100 list. Co-filing patterns matter too: the strongest co-assignee pair shares 360 records, indicating close collaboration between a large-molecule originator and a formulation specialist rather than independent parallel filing.
Go past this page: query the whole subcutaneous delivery and hyaluronidase corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company's registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.
Help us improve
Something wrong, out of date, or missing on this page? Tell us and it goes straight to the team that maintains it.
This page